Young Mania Rating Scale (YMRS)
Also known as: YMRS
The YMRS is an 11-item clinician-administered rating scale designed to assess the severity of manic and hypomanic symptoms in bipolar disorder. Developed by Young and colleagues in 1978, it is the gold standard outcome measure in bipolar disorder research and the primary efficacy endpoint in mood stabilizer and antipsychotic trials for acute mania. The YMRS captures core mania features (elevated mood, increased goal-directed activity, racing thoughts, reduced need for sleep, increased talkativeness, distractibility, and irritability) and is sensitive to both pharmacological and psychotherapeutic interventions.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
The YMRS is the primary outcome measure for acute mania in bipolar I disorder. Use it at baseline to establish mania severity, at regular intervals (weekly during acute hospitalization, biweekly during intensive outpatient treatment, monthly during maintenance) to monitor mood stability and medication response. The YMRS is essential in clinical trials of mood stabilizers (lithium, valproate, carbamazepine) and antipsychotics (quetiapine, olanzapine, risperidone, aripiprazole). It is less useful for diagnosing bipolar disorder (diagnosis requires structured interview and DSM-5 criteria) or for assessing depression in bipolar disorder (use depression-specific scales like MADRS or PHQ-9). The YMRS is appropriate for adults with bipolar disorder; pediatric bipolar disorder requires youth-specific modifications.
Strengths & limitations
- Gold standard outcome measure with extensive validation in bipolar disorder research; recognized by FDA and major bipolar disorder clinical guidelines as primary efficacy measure in mania trials.
- Comprehensive symptom coverage: captures core mania features (mood, activity, sleep, thought content, irritability) relevant to both clinical and research assessment.
- Strong interrater reliability (ICC ≥0.90) with clear behavioral anchors; standardized administration training widely available.
- Highly sensitive to mood stabilizer and antipsychotic response; rapid change (within days to weeks) makes it valuable for real-time clinical decision-making.
- Weighted item structure: clinically important symptoms (elevated mood, grandiosity, goal-directed activity) weighted more heavily than ancillary symptoms (distractibility).
- Clinician administration required; requires training and direct patient observation. Not feasible for remote or telephone assessment in some contexts.
- Does not assess depression or mixed features; bipolar patients with depression or mixed manic-depressive episodes require supplementary depression rating scales (MADRS, PHQ-9).
- Modest ceiling effects in very severe or psychotic mania; score range (0–60) may cluster extreme cases, reducing sensitivity to incremental improvement in most severe patients.
- Limited assessment of cognitive and functional domains; supplementary measures recommended to capture impairment in work, school, or social functioning.
- Item 3 (sexual interest/behavior) may be sensitive to gender, culture, and individual variability; clinician must probe carefully without judgment.
Frequently asked
What is the difference between YMRS scores in mania versus hypomania, and are cutoffs different?
Mania and hypomania are on a continuum of mood elevation intensity and duration. Mania (DSM-5) requires ≥7 consecutive days of elevated mood + functional impairment; hypomania requires ≥4 consecutive days without hospitalization/marked impairment. YMRS reflects severity at a point in time, not duration. A YMRS = 20 could be mania or hypomania depending on symptom duration and functional impact. Standard YMRS cutoffs (≥20 = moderate severity) apply to both; clinical context (episode duration, functional impairment, hospitalization) differentiates mania from hypomania.
How quickly do mood stabilizers and antipsychotics typically reduce YMRS scores?
Antipsychotics (quetiapine, olanzapine, risperidone) often show rapid YMRS improvement within 24–72 hours (sedation, reduced agitation) but core mania symptoms (elevated mood, goal-directed activity) may take 1–4 weeks. Mood stabilizers (lithium, valproate) are slower, typically showing ≥30% reduction over 2–4 weeks, with full response in 4–8 weeks. In acute severe mania, combination antipsychotic + mood stabilizer is typical. Monitor YMRS weekly during acute phase to detect response early and guide treatment adjustments.
Can I use YMRS to monitor mood in maintenance treatment, or is it only for acute mania?
YMRS can be used in maintenance, but is most sensitive to acute/subacute changes. In euthymic (stable) patients, YMRS is usually ≤12, with little variability over months. Small YMRS elevations (15–20) may precede full manic relapse by days to weeks. Many clinicians use YMRS every 4–12 weeks in maintenance; monthly or more frequent administration provides early warning of mood shifts. For maintenance, also monitor sleep (early sign of relapse), and use mood charting (daily/weekly mood ratings) for finer detection of mood changes.
What does a YMRS score of 15 mean clinically? Is the patient in mania?
YMRS = 15 indicates mild mania or hypomanic symptoms (some mood elevation, mild goal-directed activity increase, mild sleep reduction). Clinical context matters: Is this an acute exacerbation in a previously euthymic patient (concerning, may require intervention)? Or is it baseline for a patient on long-term maintenance (less concerning if functional and stable)? If YMRS = 15 is new, assess trend (increasing or stable), associated symptoms, and functional impact. Rising YMRS in previously euthymic patient warrants medication adjustment to prevent further escalation.
Should I administer YMRS to patients in mixed states or with predominant depression?
YMRS measures mania/hypomania severity and may be low (≤12) even in mixed states with dysphoric mood and depressive features. If you suspect mixed features or concurrent depression, administer YMRS plus a depression scale (MADRS, HAM-D) simultaneously. Some patients have elevated YMRS (mania symptoms) AND elevated depression scores (simultaneous depressive symptoms), which indicates dysphoric or mixed mania—a distinct state requiring different treatment (often add antidepressant cautiously with mood stabilizer).
Is the self-report YMRS (Altman Self-Rating Mania Scale) as valid as the clinician-administered YMRS?
The Altman Self-Rating Mania Scale (ASRM, 5 items) is shorter and correlates with YMRS but is less sensitive and specific. Self-report is problematic in acute mania because patients often lack insight ('I feel great, nothing is wrong'). ASRM is occasionally used for maintenance or longitudinal self-monitoring by euthymic patients, but clinician-administered YMRS remains the gold standard for clinical trials and acute assessment. Do not substitute ASRM for YMRS in research or serious clinical decisions.
Sources
- Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978). A rating scale for mania: Reliability, validity and sensitivity. British Journal of Psychiatry, 133(5), 429–435. DOI: 10.1192/bjp.133.5.429 ↗
- Altman, E. G., Hedeker, D., Peterson, J. L., & Davis, J. M. (1994). The Altman Self-Rating Mania Scale. Biological Psychiatry, 42(12), 948–955. link ↗
- Muralidharan, K., & Koshy, G. (2005). A review of the Mania Rating Scale instruments and their role in bipolar disorder. Indian Journal of Psychiatry, 47(1), 9–15. link ↗
How to cite this page
ScholarGate. (2026, June 3). Young Mania Rating Scale (YMRS). ScholarGate. https://scholargate.app/en/psychiatry/manic-state-rating-scale
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Brief Psychiatric Rating ScalePsychiatry↔ compare
- Dissociative Experiences ScalePsychiatry↔ compare
- Positive and Negative Syndrome ScalePsychiatry↔ compare